Kineta, Inc. KA
0.57 USD 0.00 (+0.00%)
At closeSep 18, 2024, 4:00 PM EDT
0.56 Day range 0.825
0.3339 52-week range 5.39
- YTD
- 0.00%
- 1 year
- 0.00%
News
prnewswire.com TuHURA Biosciences Completes Acquisition of Kineta Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA…
prnewswire.com TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals TAMPA, Fla. and SEATTLE , June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome…
prnewswire.com TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg dose level throughout the trial's every two weekly dosing interval (Q2W)…
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS…
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS…
accesswire.com TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and…
globenewswire.com Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end.
globenewswire.com Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer…
globenewswire.com Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1 TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients…
globenewswire.com Kineta, Inc Transitioning from Nasdaq to OTC Markets Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of…
globenewswire.com Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer Effective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for enrollment in the clinical study
prnewswire.com TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer 30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD1…
globenewswire.com Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences TuHURA has an exclusive right to negotiate to acquire Kineta's KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a…
prnewswire.com TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
globenewswire.com Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
benzinga.com Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.
benzinga.com Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
globenewswire.com Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
globenewswire.com Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
globenewswire.com KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts No dose limiting toxicities observed at any dose level Cleared fifth of…
benzinga.com Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of…
benzinga.com Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
globenewswire.com Kineta Announces Restructuring and Exploration of Strategic Alternatives SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune…
globenewswire.com Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune…- benzinga.com Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Aditxt, Inc. (NASDAQ: ADTX) shares gained 68.6% to $1.45. Aditxt signed asset purchase agreement to acquire 50% ownership of Global Response Aid with rights to manufacture and market…
- benzinga.com Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
- benzinga.com Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the…
- benzinga.com Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who…